PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

BACKGROUND. PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These biomarkers have each succeeded and failed in predicting responders for different cancer types. We sought to describe the PD-L1 expressio...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JCI Insight
Prif Awduron: Yarchoan, Mark, Albacker, Lee A., Hopkins, Alexander C., Montesion, Meagan, Murugesan, Karthikeyan, Vithayathil, Teena T., Zaidi, Neeha, Azad, Nilofer S., Laheru, Daniel A., Frampton, Garrett M., Jaffee, Elizabeth M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Clinical Investigation 2019
Pynciau:
Clinical Medicine
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482991/
https://ncbi.nlm.nih.gov/pubmed/30895946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.126908
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg